Pages that link to "Q54076740"

The following pages link to Baseline HIV drug resistance profile predicts response to ritonavir-saquinavir protease inhibitor therapy in a community setting. (Q54076740):

Displaying 47 items.

• Selection of high-level resistance to human immunodeficiency virus type 1 protease inhibitors (Q24554340) (← links)
• Low level of cross-resistance to amprenavir (141W94) in samples from patients pretreated with other protease inhibitors (Q33595278) (← links)
• Pre-existing minority drug-resistant HIV-1 variants, adherence, and risk of antiretroviral treatment failure (Q33672541) (← links)
• Genotypic testing for human immunodeficiency virus type 1 drug resistance (Q33906239) (← links)
• Comparison of DNA sequencing and a line probe assay for detection of human immunodeficiency virus type 1 drug resistance mutations in patients failing highly active antiretroviral therapy (Q33971104) (← links)
• Monitoring resistance to human immunodeficiency virus type 1 protease inhibitors by pyrosequencing (Q33971117) (← links)
• Human immunodeficiency virus type 1 drug resistance testing: a comparison of three sequence-based methods (Q33972550) (← links)
• A novel phenotypic drug susceptibility assay for human immunodeficiency virus type 1 (Q33979107) (← links)
• Rapid and simple phenotypic assay for drug susceptibility of human immunodeficiency virus type 1 using CCR5-expressing HeLa/CD4(+) cell clone 1-10 (MAGIC-5) (Q33981401) (← links)
• Variant human immunodeficiency virus type 1 proteases and response to combination therapy including a protease inhibitor (Q33981706) (← links)
• Diversity and complexity of HIV-1 drug resistance: a bioinformatics approach to predicting phenotype from genotype (Q34032267) (← links)
• Longitudinal use of a line probe assay for human immunodeficiency virus type 1 protease predicts phenotypic resistance and clinical progression in patients failing highly active antiretroviral therapy (Q34108198) (← links)
• Clinical monitoring of HIV-1 infection in the ERA of antiretroviral resistance testing (Q34122359) (← links)
• Systematic evaluation of allele-specific real-time PCR for the detection of minor HIV-1 variants with pol and env resistance mutations (Q34331628) (← links)
• The pharmacogenomics of HIV therapy. (Q34574033) (← links)
• Evaluation of drug resistance in HIV infection (Q34805974) (← links)
• HIV-1 drug resistance: can we overcome? (Q34974754) (← links)
• Initial therapy of HIV infection (Q34992631) (← links)
• Natural polymorphisms and unusual mutations in HIV-1 protease with potential antiretroviral resistance: a bioinformatic analysis. (Q35120811) (← links)
• Sources and magnitude of intralaboratory variability in a sequence-based genotypic assay for human immunodeficiency virus type 1 drug resistance (Q35156231) (← links)
• Enhancing Lay Counselor Capacity to Improve Patient Outcomes with Multimedia Technology (Q35955487) (← links)
• Updated clinical pharmacologic considerations for HIV-1 protease inhibitors (Q36223724) (← links)
• Identification of HIV inhibitors guided by free energy perturbation calculations (Q36708826) (← links)
• Evolution of resistance to drugs in HIV-1-infected patients failing antiretroviral therapy (Q36900004) (← links)
• Masivukeni: development of a multimedia based antiretroviral therapy adherence intervention for counselors and patients in South Africa (Q36906315) (← links)
• The Genetic Basis of HIV-1 Resistance to Reverse Transcriptase and Protease Inhibitors. (Q37018369) (← links)
• HIV-1 genotypic resistance patterns predict response to saquinavir-ritonavir therapy in patients in whom previous protease inhibitor therapy had failed (Q37021823) (← links)
• Cost-effectiveness of enfuvirtide for treatment-experienced patients with HIV in Italy (Q38324341) (← links)
• Antiviral potency of HAART regimens and clinical success are not strictly coupled in real life conditions: evidence from the MASTER-1 study (Q38932618) (← links)
• Comparison of human immunodeficiency virus type 1 RNA sequence heterogeneity in cerebrospinal fluid and plasma (Q39462662) (← links)
• Identification of genotypic changes in human immunodeficiency virus protease that correlate with reduced susceptibility to the protease inhibitor lopinavir among viral isolates from protease inhibitor-experienced patients (Q39606435) (← links)
• Comparative analysis of two commercial phenotypic assays for drug susceptibility testing of human immunodeficiency virus type 1. (Q39626204) (← links)
• Determinants of sustained virological suppression in indigent, HIV-infected patients: is single protease inhibitor-based antiretroviral therapy truly highly active? (Q39689549) (← links)
• Complementation in cells cotransfected with a mixture of wild-type and mutant human immunodeficiency virus (HIV) influences the replication capacities and phenotypes of mutant variants in a single-cycle HIV resistance assay (Q39989338) (← links)
• Clinical Pharmacologic Considerations for HIV-1 Protease Inhibitors (Q40695402) (← links)
• Selection of resistance in protease inhibitor-experienced, human immunodeficiency virus type 1-infected subjects failing lopinavir- and ritonavir-based therapy: mutation patterns and baseline correlates (Q41902281) (← links)
• Sociodemographic correlates of HIV drug resistance and access to drug resistance testing in British Columbia, Canada (Q41932161) (← links)
• Amide hydrogen exchange in HIV-1 subtype B and C proteases--insights into reduced drug susceptibility and dimer stability. (Q42184665) (← links)
• A randomized trial of nelfinavir, ritonavir, or delavirdine in combination with saquinavir-SGC and stavudine in treatment-experienced HIV-1-infected patients (Q43759278) (← links)
• Baseline antiretroviral drug susceptibility influences treatment response in patients receiving saquinavir-enhancing therapy (Q43822039) (← links)
• Longitudinal use of phenotypic resistance testing to HIV-1 protease inhibitors in patients developing HAART failure (Q44062987) (← links)
• Ritonavir plus saquinavir versus single protease inhibitor therapy in protease inhibitor-naive HIV-infected patients: the Swiss HIV Cohort Study (Q44224686) (← links)
• Genotyping in HIV drug resistance mutations: epidemiology in 145 patients (Q44260558) (← links)
• The prevalence of reduced zidovudine susceptibility in zidovudine-naive, antiretroviral-experienced HIV-1-infected patients. (Q44606303) (← links)
• Factors associated with resistance to human immunodeficiency virus protease inhibitors (Q45158683) (← links)
• Identification of key mutations in HIV reverse transcriptase gene can influence the clinical outcome of HAART. (Q54003890) (← links)
• Outcome Impacts Due to Pathogen-Specific Antimicrobial Resistance: A Narrative Review of Published Literature (Q89879024) (← links)